NDRA vs CSTL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CSTL Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Castle Biosciences, Inc. Common Stock (CSTL) driven by superior Momentum & Technical, Options & Structure while NDRA counters with relative strength in Growth & Margin. Fundamentally, NDRA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CSTL at N/M Forward P/E and -7.4% operating margin (+23.9% YoY). In options structure, NDRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CSTL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NDRA | CSTL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.6M | $1.0B | Larger Scale | CSTL |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +23.9% | Higher Growth | CSTL |
| Operating Margin (TTM) Profitability | 0.0% | -7.4% | Higher Margin | NDRA |
| Net Profit Margin Profitability | 0.0% | -6.1% | Higher Margin | NDRA |
| Return on Equity (ROE) Capital Efficiency | -152.0% | -4.9% | Higher ROE | CSTL |
| 52-Week Range Position Momentum | 37% ($3โ$7) | 57% ($18โ$44) | Stronger Trend | CSTL |
| Beta / 30D Volatility Risk Regime | 0.71ฮฒ ยท 48% Vol | 1.18ฮฒ ยท 57% Vol | Lower Realized Risk | NDRA |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 49.3 / 100 (HOLD) | Higher Composite | CSTL |